Ionis Pharmaceuticals Announces Leadership Transition

Ionis Pharmaceuticals ( (IONS) ) has shared an update.

On June 12, 2025, Ionis Pharmaceuticals announced the retirement of Richard Geary, Ph.D., effective January 2026, after a 30-year tenure during which he led the development of several key medicines. Holly Kordasiewicz, Ph.D., will succeed him as executive vice president and chief development officer, bringing her extensive experience in neurology drug development to support Ionis’ growth and innovation in the biotechnology sector.

The most recent analyst rating on (IONS) stock is a Hold with a $55.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.

Spark’s Take on IONS Stock

According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.

Ionis Pharmaceuticals’ overall score is primarily impacted by its challenging financial performance, characterized by persistent losses and high leverage. Despite these financial concerns, the company exhibits strong technical momentum and positive earnings call outcomes, reflecting improved guidance and strategic product launches. The valuation remains weak due to negative earnings, but the positive corporate events provide some support for future growth prospects.

To see Spark’s full report on IONS stock, click here.

More about Ionis Pharmaceuticals

Ionis Pharmaceuticals is a pioneer in RNA-targeted medicines, with a focus on neurology, cardiology, and other areas of high patient need. The company has a robust pipeline and six marketed medicines, leveraging its deep understanding of disease biology and innovative technology to deliver life-changing therapies.

Average Trading Volume: 1,634,347

Technical Sentiment Signal: Hold

Current Market Cap: $5.86B

For an in-depth examination of IONS stock, go to TipRanks’ Overview page.